APO M250 Pill - blue & pink capsule-shape, 19mm
Pill with imprint APO M250 is Blue & Pink, Capsule-shape and has been identified as Mycophenolate Mofetil 250 mg. It is supplied by Apotex Corp.
Mycophenolate mofetil is used in the treatment of nephrotic syndrome; organ transplant, rejection prophylaxis; graft-versus-host disease and belongs to the drug class selective immunosuppressants. There is positive evidence of human fetal risk during pregnancy. Mycophenolate mofetil 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for APO M250




Mycophenolate Mofetil
- Imprint
- APO M250
- Strength
- 250 mg
- Color
- Blue & Pink
- Size
- 19.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Selective immunosuppressants
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Apotex Corp.
- Inactive Ingredients
-
croscarmellose sodium,
magnesium stearate,
gelatin,
sodium lauryl sulfate,
ferric oxide red,
titanium dioxide,
indigotindisulfonate sodium,
shellac,
alcohol,
isopropyl alcohol,
butyl alcohol,
propylene glycol,
ammonia,
ferrosoferric oxide,
potassium hydroxide,
water
Note: Inactive ingredients may vary.
Labelers / Repackagers
NDC Code | Labeler / Repackager |
---|---|
60505-2968 (Discontinued) | Apotex Corp. |
68084-0587 (Discontinued) | Amerisource Health Services |
Related images for "APO M250"
More about mycophenolate mofetil
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (59)
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
- Drug Information
- Mycophenolate (Intravenous) (Advanced Reading)
- Mycophenolate mofetil (Advanced Reading)
- Mycophenolate Mofetil Capsules
- Mycophenolate Mofetil Tablets
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.